


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



四环医药  
*SihuanPharm*

**Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0460)**

## **VOLUNTARY ANNOUNCEMENT HUIHENG BIOPHARMACEUTICAL'S DRUG SEMAGLUTIDE INJECTION OBTAINED APPROVAL FOR CLINICAL TRIAL**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, Huisheng a peripheral neuropathy drug developed by Huisheng Biologicals, Co., Ltd. (“**Huisheng Biopharmaceutical**”), a non-wholly owned subsidiary of the Group, has been approved for clinical trials from the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (“**China**”) of Semaglutide Injection for the treatment of type 2 diabetes. In addition, Thioctic Acid Injection, a peripheral neuropathy (PN) drug developed by Huisheng Biopharmaceutical, has recently obtained the drug registration approval from NMPA, which is deemed to have passed the consistency evaluation on quality and efficacy of generic drugs.

### **About Semaglutide Injection**

Semaglutide is a long-acting GLP-1 receptor agonist (GLP-1RA) injected once a week, which not only has the potential to potently lower glucose, but also to significantly reduce weight, lower blood pressure, improve lipid profiles and reduce the risk of major cardiovascular adverse events, thereby increasing patient compliance and improving quality of life over the classic GLP-1 receptor agonist drug liraglutide. It is recommended for use in patients with type 2 diabetes mellitus (T2DM), cardiovascular disease or patients at very high cardiovascular risk.

Semaglutide injection was first launched in the US in December 2017 and by 2022, global sales had exceeded US\$10 billion. The product was approved for entry into the PRC market in 2021 and was included in the national medical insurance catalogue in the same year. Sales in the Greater China region exploded in 2022 with US\$311 million in sales.

## **About Lipoic Acid Injection**

Lipoic Acid is an antioxidant that inhibits lipid peroxidation, increases blood flow to neurotrophic vessels, improves neurological Na<sup>+</sup>-K<sup>+</sup>-ATPase activity, directly scavenges reactive oxygen clusters and free radicals, and protects vascular endothelial function. It can be used to treat diabetic peripheral neuropathy and is recommended in the “Expert Consensus on the Management of Diabetic Neuropathy (2021 Edition)”.

The number of Diabetic Peripheral Neuropathy (DPN) patients in China accounts for more than 50% of diabetes patients, and at present, there are about 140 million diabetes patients in China. Thioctic Acid Injection is a Category B drug under the National Reimbursement Drug List (2022 Edition). According to IQVIA data, the sample hospitals’ sales volume of Lipoic Acid injection in 2011 exceeded RMB1 billion in China.

## **About Huisheng Biopharmaceutical**

Huisheng Biopharmaceutical is a biopharmaceutical company under Sihuan Pharmaceutical, a large domestic pharmaceutical and medical aesthetics group, focusing on the areas of diabetes and complications. After eight years of construction and development, Huisheng Biopharmaceutical has become one of the few companies in China that has achieved full product coverage in the field of diabetes and related complications, and integrated the whole industrial chain of R&D, production and sales. The company currently has a world-class R&D team of more than 200 people with rich experience in diabetes drug research and development. At present, it has more than 40 products in the research product pipeline of diabetes and complications, covering a full range of second-, third-, and new-generation insulin (covering basic, premixed and quick-acting etc.), innovative drugs with the latest mechanism, such as SGLT-2i, GLP-1a, and other hypoglycemic drugs and complication drugs. Huisheng Biopharmaceutical is committed to providing full-process, all-round integrated treatment solutions for diabetic patients, serving patients and making health easier.

## **About Sihuan Pharmaceutical**

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 4 July 2023

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.*